Table 3. Comparison of factors associated with treatment efficacy of telaprevir, peginterferon and ribavirin triple therapy in Japanese patients infected with HCV-1b identified by multivariate analysis

Factor	≥3.0 log fall in HCV RNA (at 24 h)	HCV RNA loss (at 2 weeks)	HCV RNA loss (at 4 weeks)	HCV RNA loss (at 12 weeks)	Sustained virological response
Core aa 70 and 91	Arg70 and Leu91 p = 0.015 3.99 (1.31–12.2)*				Arg70 p = 0.055 3.15 (0.97–10.2)*
IL28B rs8099917				genotype TT p = 0.042 10.3 (1.08–98.0)*	genotype TT p < 0.001 9.94 (3.05–32.4)*
Others	body mass index p = 0.061 3.24 (0.95–11.1)*	platelet count p = 0.014 6.99 (1.49–32.8)*	body mass index p = 0.069 3.47 (0.91–13.3)* history of blood transfusion p = 0.026 4.29 (1.86–15.6)*	sex p = 0.036 11.0 (1.16–100)*	

Only variables that achieved statistical significance ($p < 0.05$) or marginal significance ($p < 0.10$) on multivariate logistic regression are shown. * OR (95% CI).

of core region also affect viral dynamics during triple therapy.

Two studies showed that aa substitution of the core region and genetic variation near *IL28B* gene affected viral dynamics during treatment, and sustained virological response to 48-week PEG-IFN plus ribavirin therapy in patients infected with HCV-1 [27, 28]. Furthermore, a recent report also showed that aa substitutions of core region might be used to predict very early dynamics (within 48 h) after the start of triple therapy of telaprevir with PEG-IFN and ribavirin [29]. In the present study, multivariate analysis identified substitution of aa 70 and 91 as a predictor of ≥3.0 log fall in HCV RNA level at 24 hours (i.e. viral dynamics of very early phase) and sustained virological response, and rs8099917 as a predictor of HCV RNA loss at 12 weeks (i.e. viral dynamics of later phase) and sustained virological response. This study is the first to report that genetic variation near *IL28B* gene and aa substitution of the core region affect viral dynamics of different phases during triple therapy, and probably explains why the combination of these independent factors is very useful as pretreatment predictors of sustained virological response by triple therapy [22]. The underlying mechanisms of the different viral dynamics to treatment are still unclear, and further studies based on a larger number of patients are necessary to investigate the present results.

Previous data indicated that absence of advanced liver fibrosis and male gender were positive predictors of virological response to 48-week PEG-IFN plus ribavirin therapy [13, 28]. The present study also showed that higher levels of platelet count at 2 weeks, as a surrogate marker of milder liver fibrosis, and male gender at 12 weeks were significant positive predictors of HCV RNA loss during triple therapy. The other positive predictors were absence of history of blood transfusion at 4 weeks and higher levels of body mass index at 24 h and 4 weeks, but the underlying mechanisms are still unclear. Thus, this report identified the pretreatment factors that could predict viral dynamics during triple therapy, but this study, based on a small number of patients, might provide misleading results (e.g. possible type error). Further studies of a larger number of patients are required to explore predictors, including viral- and host-related factors.

The limitations of the present study were that aa substitutions in areas other than the core region and NS5A-ISDR of the HCV genome, such as the interferon/ribavirin resistance determining region (IRRDR) [30], were not examined. Furthermore, HCV mutants with aa conversions for resistance to telaprevir during triple therapy, such as the 156S mutation [31], were also not investigated. In this regard, telaprevir-resistant HCV mutants were reported to be susceptible to IFN in both in vivo and in vitro studies [32, 33]. Thus, viral factors before and during triple therapy should be investigated in

future studies, and identification of these factors should facilitate the development of more effective therapeutic regimens.

In conclusion, this study identified genetic variation near *IL28B* gene and aa substitution of the core region as predictors of viral dynamics during triple therapy of telaprevir/PEG-IFN/ribavirin in Japanese patients infected with HCV-1b. Further large-scale prospective studies are necessary to investigate whether the present results relate to the efficacy of the triple therapy, and further understanding of the complex interaction between virus- and host-related factors should facilitate the development of more effective therapeutic regimens.

Acknowledgment

This study was supported in part by a Grant-in-Aid from the Ministry of Health, Labor and Welfare, Japan.

References

1 Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L, Hensel F, Petry W, Häussinger D: Progress of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687–1695.

2 Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin: Irish Hepatology Research Group. N Engl J Med 1999;340:1228–1233.

3 Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M, Kumada H: Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005;75:27–34.

4 Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling MH, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958–965.

5 Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–982.

6 Lin C, Kwong AD, Perni RB: Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006;6:3–16.

7 Modi AA, Hoofnagle JH: New therapies for hepatitis C. Hepatology 2007;46:615–617.

8 Zeuzem S: Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients. J Hepatol 2008;49:157–159.

9 McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, PROVE1 Study Team: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827–1838.

10 Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, PROVE2 Study Team: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839–1850.

11 McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, PROVE3 Study Team: Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292–1303.

12 Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Association of amino acid substitution pattern in core protein of hepatitis C virus genotype1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005;48:372–380.

13 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007;46:403–410.

14 Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE: Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 2007;81:8211–8224.

15 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007;46:1357–1364.

16 Fishman SL, Factor SH, Balestrieri C, Fan X, Dibisceglie AM, Desai SM, Benson G, Branch AD: Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin Cancer Res 2009;15:3205–3213.

17 Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401.

18 Tanaka Y, Nishida N, Sugiyama M, et al: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–1109.

19 Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100–1104.

20 Rauch A, Kutalik Z, Descombes P, et al: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338–1345.

21 Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798–801.

22 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H: Amino acid substitution in HCV core region and genetic variation near *IL28B* gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010;52:421–429.
23 Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K: Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990;87:9524–9528.
24 Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77–81.
25 Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y: A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001;46:471–477.
26 Suzuki A, Yamada R, Chang X, et al: Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginie deminase 4, are associated with rheumatoid arthritis. Nat Genet 2003;34:395–402.
27 Thompson AJ, Muir AJ, Sulkowski MS, et al: Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Hepatitis C Virus-1 Patients. Gastroenterology 2010;139:120–129.
28 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007;79:1686–1695.
29 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H: Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. J Med Virol 2010;82: 575–582.
30 El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H: Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008;48:38–47.
31 Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, Lin K, Ma S, Wei YY, Perni RB, Kwong AD: In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005;280:36784–36791.
32 Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S: Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46: 640–648.
33 Zhou Y, Müh U, Hanzelka BL, Bartels DJ, Wei Y, Rao BG, Brennan DL, Tigges AM, Swenson L, Kwong AD, Lin C: Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007;282:22619–22628.

Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma

Yusuke Kawamura, MD[1,3], Yasuji Arase, MD[1–3], Kenji Ikeda, MD[1,3], Yuya Seko, MD[1,3], Norihiro Imai, MD[1,3], Tetsuya Hosaka, MD[1,3], Masahiro Kobayashi, MD[1,3], Satoshi Saitoh, MD[1,3], Hitomi Sezaki, MD[1,3], Norio Akuta, MD[1,3], Fumitaka Suzuki, MD[1,3], Yoshiyuki Suzuki, MD[1,3], Yuki Ohmoto, MD[2,3], Kazuhisa Amakawa, MD[2,3], Hiroshi Tsuji, MD[2,3] and Hiromitsu Kumada, MD[1,3]

OBJECTIVES: **The aim of this study was to determine the incidence and risk factors of hepatocellular carcinoma (HCC), and to elucidate the utility of two non-invasive predictive procedures for liver fibrosis: the aspartate aminotransferase (AST) to platelet ratio index (APRI) and the BARD score (which includes the following three variables: body mass index, AST/alanine aminotransferase ratio, and diabetes) in the prediction of HCC in a large population of Japanese patients with non-alcoholic fatty liver disease (NAFLD).**

METHODS: **This was a retrospective cohort study conducted at a public hospital. Study subjects included 6,508 patients with NAFLD diagnosed by ultrasonography. The median follow-up period was 5.6 years. The primary end point was the onset of HCC. Evaluation was performed using Kaplan–Meier methodology and Cox's proportional hazards analysis.**

RESULTS: **In all, 16 (0.25%) new cases with HCC were diagnosed during the study. The cumulative rates of NAFLD-related HCC were 0.02% at year 4, 0.19% at year 8, and 0.51% at year 12. The annual rate of new HCC was 0.043%. Multivariate analysis identified serum AST level ≥40 IU/L (hazard ratio (HR): 8.20; 95% confidence interval (95% CI): 2.56–26.26; $P<0.001$), platelet count $<150\times10^3/\mu l$ (HR: 7.19; 95% CI: 2.26–23.26; $P=0.001$), age ≥60 years (HR: 4.27; 95% CI: 1.30–14.01; $P=0.017$), and diabetes (HR: 3.21; 95% CI: 1.09–9.50; $P=0.035$) as independent risk factors for HCC. With regard to the APRI, 184 patients (2.83%) were considered to have significant fibrosis (equivalent to non-alcoholic steatohepatitis (NASH) stage 3–4). The cumulative rate of HCC was significantly higher in this group (HR: 25.03; 95% CI: 9.02–69.52; $P<0.001$). In contrast, regarding the BARD score, 3,841 (59%) patients were considered to have advanced fibrosis (NASH stage 3–4). However, no significant associations between the BARD score and the incidence of HCC were observed (HR: 1.16; 95% CI: 0.40–3.37; $P=0.780$).**

CONCLUSIONS: **This retrospective study indicates that the annual incidence rate of HCC among Japanese NAFLD patients is low. Elderly NAFLD patients with diabetes, elevated serum AST, and especially thrombocytopenia (suggested to be associated with advanced liver fibrosis) should be monitored carefully during follow-up that includes using the APRI to ensure early diagnosis and treatment of HCC.**

Am J Gastroenterol advance online publication, 18 October 2011; doi:10.1038/ajg.2011.327

INTRODUCTION

Hepatocellular carcinoma (HCC) is a common malignancy worldwide, and its incidence is increasing in Asia and in the United States (1–3). Chronic viral hepatitis and liver cirrhosis after infection with hepatitis B and C viruses have important roles in the development of HCC (4–5). However, a substantial proportion (5–10%) of Japanese patients with HCC are negative for markers of hepatitis B and C viruses (6–8). In addition to viral infection, non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease in western countries (9–12),

[1]Department of Hepatology, Toranomon Hospital, Tokyo, Japan; [2]Health Management Center, Toranomon Hospital, Tokyo, Japan; [3]Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan. **Correspondence:** Yusuke Kawamura, MD, Department of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo 105-8470, Japan. E-mail: k-yusuke@toranomon.gr.jp
Received 5 April 2011; accepted 23 August 2011

and more recently in many Asian nations (13,14). NAFLD is sometimes considered to be the liver component of metabolic syndrome (15–17). It is associated with obesity, dyslipidemia, pituitary dysfunction, hypertension, sleep apnea, and type 2 diabetes mellitus (18–24). In particular, patients with non-alcoholic steatohepatitis (NASH), a subcategory of NAFLD, are at a higher risk for the incidence of HCC (25). At this stage, NASH can only be diagnosed by histopathology. Despite being common and potentially serious, the natural history of NAFLD remains poorly defined. Most of the studies reported to date included limited numbers of highly selected patients, i.e., patients with histopathologically confirmed NAFLD who were referred to specialized tertiary care centers (26–31). However, in reality, larger numbers of NAFLD patients are diagnosed by ultrasonography (US) alone. To our knowledge, no information about the incidence and risk factors of HCC in Japanese individuals with NAFLD diagnosed by US has been published.

The number of patients with NAFLD is predicted to increase in the future, and it is unlikely that all NAFLD patients will be diagnosed by histopathological examination of liver biopsy due to the potential risks associated with fat deposition and fibrosis in the liver (e.g., risk of bleeding, allergy to local anesthetics, and patient refusal). Therefore, there is a need to define the clinical impact of NAFLD and risk factors for the incidence of HCC. One aim of this retrospective study was to determine the incidence and risk factors of HCC in patients with US-diagnosed NAFLD. The aspartate aminotransferase (AST) to platelet ratio index (APRI), a non-invasive index for prediction of significant fibrosis in patients with chronic hepatitis C, has been previously reported (32), and its utility in NAFLD has also been reported (33). More recently, the BARD score (which includes the three following variables: body mass index (BMI), AST/alanine aminotransferase (ALT) Ratio, and Diabetes), a non-invasive estimation formula for predicting advanced fibrosis in patients with NALFD, has also been reported (34). The other purpose of this study was to elucidate the utility of these non-invasive predictive procedures for liver fibrosis in the prediction for incidence of HCC in NAFLD patients.

METHODS

Study population

In this retrospective cohort study, we obtained the medical records of all patients in our database who were diagnosed with NAFLD by US (35) between January 1997 and December 2010 at the Department of Hepatology and the Health Management Center (Toranomon Hospital, Tokyo, Japan). Of these, 6,508 patients satisfied the following criteria: (i) past daily alcohol intake of <20 g/day; (ii) negativity for hepatitis C virus antibodies, hepatitis B surface antigen, antinuclear antibodies, and anti-mitochondrial antibodies in serum, as determined by radioimmunoassay or spot hybridization; (iii) no underlying systemic disease, such as systemic lupus erythematosus and rheumatic arthritis; (iv) no underlying metabolic disease, such as hemochromatosis, α-1-antitrypsin deficiency, and Wilson's disease; (v) no evidence of HCC on US and/or computed tomography; and (vi) follow-up period of ≥48 weeks. Clinical and laboratory data were collected from the medical records of all 6,508 patients and analyzed. The study was approved by the Institutional Review Board of our hospital.

Clinical background and laboratory data

Table 1 summarizes the clinical profile and laboratory data of NAFLD patients. The male:female ratio was 7.15:1, and the median BMI was 24.8 kg/m^2. Of the total population, 841 (12.9%) patients were hypertensive, and 536 (8.2%) patients had diabetes at the time of diagnosis of NAFLD. Hypertension was defined as seated systolic/diastolic blood pressure of $>140/>90$ mm Hg measured after 5 minutes of rest (36). Diabetes was diagnosed based on the 2003 criteria of the American Diabetes Association (37). These criteria include: (i) casual plasma glucose ≥200 mg/dl; (ii) fasting plasma glucose ≥126 mg/dl; and (iii) 2-h post-glucose (oral glucose tolerance test) ≥200 mg/dl.

Hepatitis C virus antibodies and hepatitis B surface antigen were examined at study entry. Hepatitis C virus antibodies were detected using a third-generation enzyme-linked immunosorbent assay (Abbott Laboratories, North Chicago, IL). Hepatitis B surface antigen was tested by radioimmunoassay (Abbott Laboratories).

Table 1. **Characteristics of 6,508 patients with non-alcoholic fatty liver disease**

Gender, M:F	5,709:799
Age, years[a]	49 (23–86)
Body mass index, kg/m^2 [a]	24.8 (15.9–45.1)
Hypertension, yes/no	841:5,667
Albumin, g/dl[a]	4.2 (2.9–5.1)
Total bilirubin, mg/dl[a]	0.8 (0.2–4.3)
AST, IU/L[a]	26 (11–516)
ALT, IU/L[a]	30 (7–803)
LDH, IU/L[a]	145 (49–392)
γ-GTP, IU/L[a]	53 (8–2,376)
Platelet count, $\times10^3/\mu l$[a]	226 (27–554)
Fasting plasma glucose, mg/dl[a]	99 (71–377)
Diabetes mellitus, yes/no	536:5,972
Uric acid, mg/dl[a]	6.3 (0.7–11.5)
Total cholesterol, mg/dl[a]	210 (100–521)
Triglyceride, mg/dl[a]	138 (22–1,758)
LDL cholesterol, mg/dl[a]	131 (29–270)
HDL cholesterol, mg/dl[a]	46 (5–106)
Follow-up period, days[a]	2,051 (366–11,190)

ALT, alanine aminotransferase; AST, aspartate aminotransferase; F, female; γ-GTP, gamma-glutamyl transpeptidase; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; M, male.
[a]These are expressed as median (minimum, maximum).

Medical evaluation

The diagnosis of NAFLD was based on the US finding of bright liver with stronger echoes in the hepatic parenchyma than in the renal or spleen parenchyma. US was performed using a high-resolution, real-time scanner (model SSD-2000; Aloka, Tokyo, Japan, or Mode Logic-700 MR; GE-Yokokawa Medical Systems, Tokyo, Japan). Body weight was measured in light clothing and without shoes to the nearest 0.1 kg. Height was measured to the nearest 0.1 cm. Height and weight were recorded at baseline and BMI was calculated as weight (in kg)/height (in m^2). All patients were interviewed at the Toranomon Hospital using a questionnaire that collected information on demographic characteristics, medical history, and health-related habits, including questions about alcohol intake at the time of diagnosis of NAFLD.

Follow-up and diagnosis of HCC

The observation starting point (study entry) was the time of diagnosis of NAFLD by US. After that, patients were followed up monthly to every 6 months at the Toranomon Hospital. In this cohort, 5,657 (86.9%) patients underwent US every 6 months. A blood sample was taken for routine analysis. Overall, 585 patients were lost to follow-up; these were considered as censored data in statistical analysis as the appearance of HCC was not identified in these 585 patients (38).

Histopathological examination of the liver

In patients who underwent histological examination of the liver, specimens were fixed in 10% formalin and stained with hematoxylin–eosin, Masson's trichrome, silver impregnation, and periodic acid-Schiff after diastase digestion. Fibrosis was scored using a five-grade scale proposed by Brunt *et al.* (39): stage 0, normal connective tissue; stage 1, pericellular or perivenular fibrosis in zone 3 (pericentral vein area); stage 2, pericellular or perivenular fibrosis confined to zones 2 and 3 with or without periportal fibrosis; stage 3, bridging or septal fibrosis; and stage 4, cirrhosis.

A total of 104 patients underwent histological examination, and 10 (9.6%) patients received a histological diagnosis at the time of treatment of HCC. As a result of histological diagnosis, 73 (70.2%) patients were diagnosed with NASH, 30 (28.8%) patients were diagnosed with fatty liver without fibrosis, and 1 (1.0%) patient was diagnosed with liver cirrhosis without steatosis.

APRI calculation method and prevalence of significant fibrosis

The APRI was calculated according to the following formula:

$$\text{APRI} = \frac{\text{AST level (/ULN*)}}{\text{Platelet count } (10^9/\text{l})} \times 100$$

*ULN, AST upper level of normal (33 IU/l)

As previously reported, an APRI > 1.50 is predictive of significant fibrosis (positive predictive value, 88%; negative predictive value, 64%). In association with the APRI, hepatic fibrosis was assessed using the Ishak fibrosis score (40). Significant fibrosis was defined as an Ishak score of ≥3 (presence of occasional bridging fibrosis) (32). In this study, 184 of 6,508 patients (2.83%) had an APRI > 1.50 and were therefore considered to have significant fibrosis.

BARD score calculation method and prevalence of advanced fibrosis

The BARD score consists of three variables: BMI ≥28 kg/m^2, AST/ALT ratio ≥0.8, and diabetes. The following points are given to each variable: BMI, 1 point; AST/ALT ratio, 2 points; and presence of diabetes, 1 point; thus, scores range from 0 to 4. As previously reported, a BARD score of 2–4 is associated with an odds ratio for advanced fibrosis of 17 (positive predictive value, 43%; negative predictive value, 96%) (34). In association with the BARD score, advanced fibrosis was defined as NASH stage 3–4, and in this study, 3,841 of 6,508 (59.0%) patients had a BARD score of ≥2 points, and were therefore considered to have advanced fibrosis.

Statistical analysis

The cumulative incidence rate of HCC (new cases of HCC) was calculated from study entry to diagnosis of HCC using the Kaplan–Meier method. Differences in the development of HCC between groups were tested using the log-rank test. Independent factors associated with the incidence of HCC were analyzed by Cox's proportional hazards model. The following 17 variables were analyzed as potential covariates for incidence of HCC at the time of study entry: sex, age, BMI, hypertension, diabetes, serum concentration of albumin, total bilirubin, AST, ALT, lactate dehydrogenase, γ-glutamyl transpeptidase, uric acid, total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and platelet count. Several variables were transformed into categorical data consisting of two simple ordinal numbers for univariate and multivariate analyses. All factors found to be at least marginally associated with the incidence of HCC ($P < 0.15$) in univariate analysis were entered into a multivariate Cox's proportional hazards model. A P value < 0.05 in a two-tailed test was considered significant. Data analysis was performed using The Statistical Package for Social Sciences version 16.0 for Windows (SPSS, Chicago, IL).

RESULTS

Incidence of HCC in patients with NAFLD

The follow-up period for all patients ranged from 366 to 11,190 days (median, 2,051 days). Of the 6,508 NAFLD patients, 16 (0.25%) patients developed HCC. The cumulative rate of HCC was 0.02% at the end of the 4th year, 0.19% at the end of the 8th year, and 0.51% at the end of the 12th year (**Figure 1**). The annual incidence of HCC in patients with NAFLD was 0.043%.

Effect of diabetes mellitus on the incidence of HCC in NAFLD patients

During the follow-up period, 9 of the 5,972 (0.15%) non-diabetic patients developed HCC, whereas 7 of the 536 (1.31%) diabetic patients developed HCC. The cumulative rate of HCC in non-diabetic patients was 0.0% at the end of the 4th year, 0.10% at the end of the 8th year, and 0.10% at the end of the 12th year. For diabetic patients, these rates were 0.22, 0.83, and 3.42%,



Figure 1. Cumulative rate of development of hepatocellular carcinoma in Japanese patients with non-alcoholic fatty liver disease diagnosed by ultrasonography.



Figure 2. Cumulative rate of development of hepatocellular carcinoma in Japanese patients with or without diabetes mellitus diagnosed with non-alcoholic fatty liver disease by ultrasonography.

respectively (**Figure 2**). The cumulative rate of HCC was significantly higher in patients with diabetes than in non-diabetic patients ($P<0.001$).

Factors associated with the incidence of HCC

Multivariate Cox's proportional hazards analysis identified AST level ≥40 IU/L (hazard ratio (HR): 8.20; 95% confidence interval (95% CI): 2.56–26.26; $P<0.001$), platelet count $<150\times10^3/\mu l$ (HR: 7.19; 95% CI: 2.26–23.26; $P=0.001$), age ≥60 years (HR: 4.27; 95% CI: 1.30–14.01; $P=0.017$), and diabetes (HR: 3.21; 95% CI: 1.09–9.50; $P=0.035$) to be independent factors for development of HCC in Japanese NAFLD patients diagnosed by US (**Table 2**).

Incidence of HCC in patients with APRI-estimated significant fibrosis

On the basis of APRI estimation, 10 of the 6,324 (0.16%) non-significant fibrotic patients developed HCC during the follow-up period, whereas 6 of the 184 (3.26%) significant fibrotic patients developed HCC. The cumulative rate of HCC in non-significant fibrotic patients was 0.02% at the end of the 4th year, 0.06% at the end of the 8th year, and 0.39% at the end of the 12th year. For significant fibrotic patients, these rates were 0, 4.03, and 4.03%, respectively (**Figure 3**). The cumulative rate of HCC was significantly higher in patients with significant fibrosis than in patients without significant fibrosis (HR: 25.03; 95% CI: 9.02–69.52; $P<0.001$).

Incidence of HCC in patients with BARD score-estimated advanced fibrosis

On the basis of BARD score estimation, 5 of the 2,667 (0.19%) non-advanced fibrotic patients developed HCC during the follow-up period, whereas 11 of the 3,841 (0.29%) advanced fibrotic patients developed HCC. The cumulative rate of HCC in non-advanced fibrotic patients was 0% at the end of the 4th year, 0.06% at the end of the 8th year, and 0.06% at the end of the 12th year. For advanced fibrotic patients, these rates were 0.04, 0.27, and 0.76%, respectively (**Figure 4**). However, no significant associations between the BARD score and the incidence of HCC were observed (HR: 1.16; 95% CI: 0.40–3.37; $P=0.780$).

Clinicopathological features of NAFLD patients with HCC

Table 3 summarizes the characteristics and clinical features of the 16 patients with NAFLD-related HCC. In these patients, the median period from study entry to diagnosis of HCC was 12.5 years. In 12 of these 16 (75.0%) patients, platelet count decreased from study entry to diagnosis of HCC. Furthermore, the pathological diagnosis of background liver disease, which was performed in 11 of the 16 (68.8%) patients at the time of treatment of HCC, was NASH stage 4 (cirrhosis) in 3 (27.3%) patients, NASH stage 3 (pre-cirrhosis) in 2 (18.2%) patients, NASH stage 1–2 (slight-to-moderate fibrosis) in 3 (27.3%) patients, liver cirrhosis without fatty deposition in 1 (9.1%) patient, and fatty liver without fibrosis in 2 (18.2%) patients. Thus, 8 (72.7%) of the 11 patients had NASH. In case 4 (**Table 3**), splenectomy was performed because of associated thrombocytopenia, although the platelet count was increased at the time of diagnosis of HCC.

DISCUSSION

Previous retrospective studies have reported that the incidence of HCC from NASH ranges from 4 to 27% after development of cirrhosis, although the development of HCC in the setting of NAFLD remains a rare complication (41,42). The incidence of HCC in patients with NAFLD reported in several longitudinal follow-up studies ranged from 0 to 0.5%, whereas that in patients with NASH ranged from 0 to 2.8% over a follow-up period of 19.5 years (25,43–45). According to Japanese annual health check reports, 9–30% of Japanese adults demonstrate evidence of NAFLD by US (46–48). As it is known that almost 10–20% of individuals with NAFLD have NASH, the prevalence of NASH is estimated to be 1–3% of the adult Japanese population, which represents an extremely large number of potential patients. To our knowledge, no information about the incidence of HCC after

Table 2. **Predictors of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease**

Variables	Category	Univariate analysis		Multivariate analysis	
		HR (95% CI)	*P* value	HR (95% CI)	*P* value
Gender	1: Female	1			
	2: Male	2.02 (0.69–5.93)	0.198		
Age	1: <60	1		1	
	2: ≥60	9.98 (2.73–36.49)	0.001	4.27 (1.30–14.01)	0.017
Body mass index (kg/m^2)	1: <25	1			
	2: ≥25	1.69 (0.63–4.55)	0.300		
Hypertension	1: No	1			
	2: Yes	10.26 (3.78–27.83)	<0.001		
Albumin (g/dl)	1: ≥4.0	1			
	2: <4.0	2.18 (0.78–6.17)	0.139		
Total bilirubin (mg/dl)	1: ≥1.0	1			
	2: <1.0	1.06 (0.37–3.70)	0.907		
AST (IU/L)	1: <40	1		1	
	2: ≥40	16.28 (5.65–46.96)	<0.001	8.20 (2.56–26.26)	<0.001
ALT (IU/L)	1: <50	1			
	2: ≥50	12.31 (4.24–35.70)	<0.001		
LDH (IU/L)	1: <160	1			
	2: ≥160	3.35 (1.25–8.99)	0.017		
γ-GTP (IU/L)	1: <70	1			
	2: ≥70	2.10 (0.79–5.60)	0.140		
Platelet count (×10^3/μl)	1: ≥150	1		1	
	2: <150	18.18 (6.49–50.00)	<0.001	7.19 (2.26–23.26)	0.001
Diabetes	1: No	1		1	
	2: Yes	6.08 (2.26–16.36)	<0.001	3.21 (1.09–9.50)	0.035
Uric acid (mg/dl)	1: <6.0	1			
	2: ≥6.0	1.55 (0.56–4.30)	0.397		
Total cholesterol level (mg/dl)	1: ≥220	1			
	2: <220	1.04 (0.38–2.87)	0.936		
Triglyceride level (mg/dl)	1: ≥150	1			
	2: <150	4.31 (0.98–19.23)	0.054		
LDL cholesterol level (mg/dl)	1: <140	1			
	2: ≥140	1.07 (0.40–2.89)	0.889		
HDL cholesterol level (mg/dl)	1: <40	1			
	2: ≥40	1.34 (0.38–4.75)	0.648		

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; F, female; γ-GTP, gamma-glutamyl transpeptidase; HDL, high-density lipoprotein; HR, hazard ratio; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; M, male.

long-term follow-up in a large number of Japanese patients with NAFLD has been previously published.

This study revealed several findings about the development of HCC in Japanese NAFLD patients. This is the first study to determine the annual rate and risk factors of newly developed HCC in a large number of Japanese patients with NAFLD diagnosed by US. In this study, the incidence of HCC calculated after long-term follow-up in NAFLD patients was 0.25%, with an annual rate of 0.043%. These low rates are similar to those reported by other groups in other countries (25,43–45). However, a total of



Figure 3. Cumulative rate of development of hepatocellular carcinoma in Japanese patients with non-alcoholic fatty liver disease diagnosed by ultrasonography according to the APRI. APRI, aspartate aminotransferase to platelet ratio index.



Figure 4. Cumulative rate of development of hepatocellular carcinoma in Japanese patients with non-alcoholic fatty liver disease diagnosed by ultrasonography according to the BARD score. BARD, body mass index, AST/alanine aminotransferase ratio, and diabetes.

15,944 patients were diagnosed as having a non-alcoholic history (past daily alcohol intake of <20 g/day) and without complicated fatty liver by US between January 1997 and December 2010 at the Department of Hepatology and the Health Management Center (Toranomon Hospital, Tokyo, Japan), and in this large population at the same institute, HCC occurred in only 2 of 15,944 (0.013%) patients during the follow-up period. In this study, the incidence of HCC in NAFLD patients was 0.25%, which is higher than that in the non-alcoholic, non-fatty liver population.

In this study, advanced age, high AST level, thrombocytopenia (marker of progression of liver fibrosis), and diabetes were identified as risk factors for the development of HCC in Japanese patients with US-diagnosed NAFLD. These results are in agreement with the previously reported risk factors of NASH-related HCC, namely advanced age, advanced fibrosis, cirrhosis, and diabetes (49). In this regard, a high serum ALT level was reported to be a surrogate for histopathological diagnosis of NAFLD (50). Clinically, most patients with NAFLD are known to have high ALT levels. Our analysis identified elevated AST levels, but not elevated ALT levels, as a risk factor for NAFLD-related HCC. The exact reason for this finding is not clear, but we speculate the following: based on the pathological features of NASH, necroinflammatory changes and perisinusoidal fibrosis usually appear around zone 3, i.e., the pericentral vein area of the liver. Among liver enzymes, the distribution of AST is closer to zone 3 than distributions of other enzymes. Thus, the correlation with high AST levels observed in this study may reflect the significance of AST as a factor related to NASH disease progression, in contrast to serum ALT levels.

Advanced liver fibrosis in NASH is considered to be an important etiological factor for the incidence of HCC. In this study, we identified a ≥10% decrease in platelet counts (relative to baseline) in 9 of the 16 patients whose NAFLD progressed to HCC. Thrombocytopenia has also been previously reported to be a risk factor for the incidence of HCC (39). Thus, it seems that the decrease in platelet count during progression is also an important etiological factor in the incidence of HCC, as it is in viral-induced hepatitis, and may indicate advancing liver fibrosis in NAFLD.

The results of this study revealed that with respect to APRI, the incidence of HCC was significantly higher in patients with an APRI of >1.5; however, no significant associations between the BARD score and the incidence of HCC were observed. **Table 3** shows the change of APRI and BARD scores from the beginning of follow-up to the time of diagnosis of HCC. At the beginning of follow-up, 5 of 16 (31.3%) patients had a >1.5 APRI. However, at the time of diagnosis of HCC, only 2 (12.5%) patients had a >1.5 APRI. Furthermore, in 8 of 16 (50.0%) patients, the APRI had improved at the time of diagnosis of HCC. Of these 8 patients, 1 patient underwent splenectomy due to associated thrombocytopenia, although the platelet count had increased at the time of diagnosis of HCC; however, 2 patients in whom the platelet count had decreased ≥10% since the beginning of follow-up were included. In contrast, with respect to the BARD score, 12 of 16 (75.0%) patients had a BARD score of ≥2, and BARD scores were maintained or increased in all cases. On the basis of this result, the BARD score may be more useful for evaluating disease progression in NAFLD patients than the APRI. Thus, although each of these fibrosis estimation procedures were previously believed to have both strengths and weaknesses, these results demonstrated that both estimations can be clinically applied for early detection of patients at high risk for HCC. Interestingly, two patients in this study with fatty liver but without fibrosis developed HCC. This finding differs from that of another large-scale study of NAFLD patients (25,43–45), which did not report the development of HCC from fatty liver without fibrosis. The above findings emphasize the need for further studies to identify factors that trigger the onset of HCC process in NAFLD patients without fibrosis, including single-nucleotide polymorphisms.

This study has certain limitations. First, this was a retrospective cohort trial. Second, the male:female ratio was strongly biased toward males. This heterogeneity makes it difficult to interpret the study results. Third, this study was not performed as a comparison to the background incidence of HCC in the Japanese general population without NAFLD and alcoholic liver disease.

Table 3. **Characteristics of patients with non-alcoholic fatty liver disease who developed hepatocellular carcinoma during follow-up**

			At study entry							At diagnosis of hepatocellular carcinoma								
Case	Sex	Diabetes	Age (yrs)	BMI (kg/m²)	AST (IU/L)	ALT (IU/L)	Platelet count (×10³/μL)	APRI	BARD score	Age (yrs)	BMI (kg/m²)	AST (IU/L)	ALT (IU/L)	Platelet count (×10³/μL)	APRI	BARD score	Treatment	Pathological diagnosis	Follow-up (yrs)
1	M	Present	41	35.4	42	50	225	0.57	4	51	40.4	26	22	82	0.96	4	Resection	NASH Stage 4 (cirrhosis)	9.9
2	M	Absent	41	29.7	77	94	146	1.61	3	63	29.0	38	32	116	0.99	3	RFA	Not performed	21.7
3	M	Absent	50	37.7	41	60	111	1.12	1	55	31.8	32	50	111	0.86	1	TACE	NASH Stage 4 (cirrhosis)	4.5
4	M	Absent	55	24.5	72	62	47	4.64	2	61	24.5	31	20	117	0.80	2	RFA	NASH Stage 4 (cirrhosis)	6.0
5	M	Absent	56	27.7	43	64	304	0.43	0	81	24.5	54	43	240	0.68	2	RFA	NASH Stage 1	24.7
6	M	Present	56	28.7	17	24	227	0.23	2	68	23.0	20	14	140	0.43	3	TACE	Not performed	12.0
7	M	Absent	59	25.3	46	60	217	0.64	2	79	23.3	20	17	206	0.29	2	RFA	Fatty liver without fibrosis	19.6
8	M	Absent	60	23.1	14	16	170	0.25	2	79	24.0	26	24	131	0.60	2	Resection	Fatty liver without fibrosis	18.8
9	M	Absent	60	28.6	31	46	161	0.58	1	73	28.3	41	46	105	1.18	3	RFA	NASH Stage 3 (pre-cirrhosis)	13.0
10	M	Present	62	23.7	41	68	222	0.56	1	84	24.7	57	52	119	1.45	3	RFA	NASH Stage 2	21.5
11	M	Present	65	29.4	60	80	138	1.32	2	72	29.1	33	26	67	1.49	4	RFA	Not performed	7.5
12	F	Absent	58	38.1	75	68	106	2.14	3	72	35.3	41	19	69	1.80	3	Resection	Liver cirrhosis	14.3
13	F	Present	63	24.2	40	32	75	1.60	3	67	25.7	36	27	71	1.54	3	TACE	Not performed	3.8
14	F	Present	64	24.4	22	20	271	0.25	3	80	24.0	31	24	225	0.42	3	RFA	NASH Stage 3 (pre-cirrhosis)	16.2
15	F	Present	68	22.1	67	54	159	1.28	3	75	22.1	49	37	162	0.92	3	RFA	Not performed	6.2
16	F	Absent	83	23.1	140	109	163	2.60	2	88	25.3	56	46	178	0.95	2	TACE	NASH Stage 2	5.3

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; F, female; BARD, body mass index, AST/ALT ratio, and diabetes; M, male; NASH, non-alcoholic steatohepatitis; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; APRI, aspartate aminotransferase to platelet ratio index.

Thus, these results do not adequately address whether NAFLD as a whole is associated with a higher risk of HCC. However, the strengths of this study include the long-term follow-up period and the inclusion of a large number of patients.

In conclusion, this retrospective study is the first to describe the cumulative incidence and risk factors of HCC in a large number of Japanese patients with NAFLD. On the basis of these results, we recommend careful monitoring and follow-up of elderly NAFLD patients with high serum AST, thrombocytopenia, and diabetes for early diagnosis and treatment of HCC.

ACKNOWLEDGMENTS

We acknowledge the editorial help of Dr FG Issa (http://www.word-medex.com.au).

CONFLICT OF INTEREST

Guarantor of the article: Yusuke Kawamura, MD.

Specific author contributions: Yusuke Kawamura: study concept and design, acquisition of data, statistical analysis, and drafting of manuscript; Yasuji Arase: acquisition of data, statistical analysis, and study supervision; Kenji Ikeda: acquisition of data; Yuya Seko: acquisition of data; Norihiro Imai: acquisition of data; Tetsuya Hosaka: acquisition of data; Masahiro Kobayashi: acquisition of data; Satoshi Saitoh: acquisition of data; Hitomi Sezaki: acquisition of data; Norio Akuta: acquisition of data; Fumitaka Suzuki: acquisition of data; Yoshiyuki Suzuki: acquisition of data; Yuki Ohmoto: acquisition of data; Hiroshi Tsuji: acquisition of data; Kazuhisa Amakawa: acquisition of data; Hiromitsu Kumada: acquisition of data.

Financial support: This study was funded by the Okinaka Memorial Institute for Medical Research and Japanese Ministry of Health, Labour and Welfare.

Potential competing interests: None.

Study Highlights

WHAT IS CURRENT KNOWLEDGE

- The incidence of hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD) reported in several longitudinal follow-up studies from non-Asian countries ranged from 0 to 0.5%, whereas that in patients with non-alcoholic steatohepatitis (NASH) ranged from 0 to 2.8%.
- Several previous studies have reported that advanced age, advanced fibrosis, cirrhosis, and diabetes are risk factors for NASH-related HCC.

WHAT IS NEW HERE

- The prevalence of HCC over a long follow-up period in Japanese patients with NAFLD diagnosed by ultrasonography was 0.25%, with an annual rate of 0.043%.
- In addition to high aspartate aminotransferase (AST) level, thrombocytopenia (suggested to be associated with advanced liver fibrosis), advanced age, and diabetes were independent risk factors for HCC in Japanese NAFLD patients.
- Non-invasive procedures used to predict liver fibrosis, such as the AST to platelet ratio index (APRI), may be useful to predict which Japanese NAFLD patients are at high risk of developing HCC.

REFERENCES

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–50.
2. Bosch X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271–85.
3. Okuda K, Fujimoto I, Hanai A *et al.* Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47:4967–72.
4. Johnson PJ, Williams R. Cirrhosis and the aetiology of hepatocellular carcinoma. J Hepatol 1987;4:140–7.
5. Ikeda K, Saitoh S, Koida I *et al.* A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47–53.
6. Yamanaka N, Tanaka T, Tanaka W *et al.* Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 1997;79:1509–15.
7. Koike Y, Shiratori Y, Sato S *et al.* Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000;32:1216–23.
8. Yotsuyanagi H, Shintani Y, Moriya K *et al.* Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus. J Infect Dis 2000;181:1920–8.
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221–31.
10. Williams R. Global changes in liver disease. Hepatology 2006;44:521–6.
11. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008;134:1682–98.
12. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009;49:306–17.
13. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009;50:204–10.
14. Watanabe S, Yaginuma R, Ikejima K *et al.* Liver diseases and metabolic syndrome. J Gastroenterol 2008;43:509–18.
15. Vega GL, Chandalia M, Szczepaniak LS *et al.* Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007;46:716–22.
16. van der Poorten D, Milner KL, Hui J *et al.* Visceral fat a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008;48:449–57.
17. Fan JG, Li F, Cai XB *et al.* Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007;22:1086–91.
18. Angulo P, Keach JC, Batts KP *et al.* Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356–62.
19. Stern SE, Williams K, Ferrannini E *et al.* Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005;54:333–9.
20. Muniyappa R, Lee S, Chen H *et al.* Current approaches for assessing insulin sensitivity and resistance *in vivo*: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008;294:E15–26.
21. Adams LA, Feldstein A, Lindor KD *et al.* Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004;39:909–14.
22. Tanné F, Gagnadoux F, Chazouillères O *et al.* Chronic liver injury during obstructive sleep apnea. Hepatology 2005;41:1290–6.
23. Kheirandish-Gozal L, Sans Capdevila O, Kheirandish E *et al.* Elevated serum aminotransferase levels in children at risk for obstructive sleep apnea. Chest 2008;133:92–9.
24. Arase Y, Suzuki F, Ikeda K *et al.* Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol 2009;44:1064–70.
25. Adams LA, Lymp JF, St Sauver J *et al.* The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–21.
26. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989;20:594–8.
27. Powell EE, Cooksley WG, Hanson R *et al.* The natural history of non-alcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74–80.
28. Teli MR, James OF, Burt AD *et al.* The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714–9.
29. Matteoni CA, Younossi ZM, Gramlich T *et al.* Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–9.
30. Dam-Larsen S, Franzmann M, Andersen IB *et al.* Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750–5.

31. Evans CD, Oien KA, MacSween RN *et al.* Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002;55:689–92.
32. Wai CT, Greenson JK, Fontana RJ *et al.* A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26.
33. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E *et al.* AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008;7:350–7.
34. Harrison SA, Oliver D, Arnold HL *et al.* Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441–7.
35. Lonardo A, Bellini M, Tartoni P *et al.* The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. Ital J Gastroenterol Hepatol 1997;29:351–6.
36. Mancia G, De Backer G, Dominiczak A *et al.* Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–87.
37. Genuth S, Alberti KG, Bennett P *et al.* Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–7.
38. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials 1984;5:348–61.
39. Brunt EM, Janney CG, Di Bisceglie AM *et al.* Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467–74.
40. Ishak K, Baptista A, Bianchi L *et al.* Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9.
41. Ratziu V, Bonyhay L, Di Martino V *et al.* Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485–93.
42. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009;115:5651–61.
43. Ekstedt M, Franzén LE, Mathiesen UL *et al.* Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44: 865–73.
44. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608–12.
45. Rafiq N, Bai C, Fang Y *et al.* Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234–8.
46. Amarapurkar DN, Hashimoto E, Lesmana LA *et al.* How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007;22:788–93.
47. Kojima S, Watanabe N, Numata M *et al.* Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003;38:954–61.
48. Hamaguchi M, Kojima T, Takeda N *et al.* The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143: 722–8.
49. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51: 1820–32.
50. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71–9.

＜短　報＞

NS5A阻害剤とNS3プロテアーゼ阻害剤併用投与における早期の抗ウイルス効果

鈴木　義之[1)*]　瀬崎ひとみ[1)]　芥田　憲夫[1)]　鈴木　文孝[1)]　瀬古　裕也[1)]
今井　則博[1)]　平川　美晴[1)]　川村　祐介[1)]　保坂　哲也[1)]　小林　正宏[1)]
斎藤　聡[1)]　荒瀬　康司[1)]　池田　健次[1)]　小林万利子[2)]　熊田　博光[1)]

緒言：C型慢性肝炎に対する現在の標準治療はペグインターフェロン（PEG-IFN）製剤とリバビリン（Riba）の併用投与が基本であるが，最近では，効果の向上と治療期間の短縮を目的に新たな蛋白合成阻害剤の併用試験が行われ良好な結果が得られることが報告されている．芥田らの報告によればPEG-IFN＋Ribaに蛋白合成阻害剤であるtelaprevirを加えた三剤併用投与では，24週間の投与で60％以上の完全著効がえられており，今後の治療の主流をなしていくと思われる[1)]．今回我々は更なる治療効果の向上を目指してNS5A阻害剤とNS3阻害剤の併用投与を行い，治療早期の抗ウイルス効果につき検討を行ったので報告する．

対象と方法：標準治療であるPEG＋Riba併用療法を24週以上行いながらも，開始前のウイルス量から2 log IU/ml以上の低下が認められなかったHCV-1b高ウイルス量のnull-responderの5例を対象とした．2種類のNS5AとNS3に対する阻害剤を経口で連日24週間投与するという治療計画であり，NS5A阻害剤は60 mgを1日1回，NS3阻害剤は600 mgを1日2回いずれも食後に併用投与した．投与初日は，1，2，4，8，12時間後に，また，24，48時間後とさらに7，15日目にHCV-RNA量を経時的に測定し，投与早期の抗ウイルス効果を解析した．HCV-RNAの測定はTaqman PCR法を用いて行い，1.2 log IU/ml未満でかつシグナルが検出されなくなった時点で陰性化したと判定した．



Fig. 1　Changes in hepatitis C (HCV) RNA concentration over duration of study treatment

結果：投与5症例の背景を示すと，男性2例（40％），年齢の中央値は60歳（53-69歳），IL-28BのSNP（rs8099917）は，TT2例，TG3例であった．また，ウイルス側の要因であるcoreの変異は70, 91においては，1例がdouble wild，1例が70 mutant，91 wildで，3例がdouble mutantであり，ISDR変異は，0が1例，1が4例であった．開始前のALT値は中央値で70 IU/l（範囲13～114），HCV-RNA量は中央値7.0 log IU/mL（範囲5.2～7.4）であった．投与後の経時的ウイルス量の変化をFig. 1に示すが，2 log IU/mL低下までにかかった時間はそれぞれ，4，8，8，8，12時間と短時間で急激なウイルス量の減少が認められた．ウイルス低下速度とIL-28B等の予測因子との関係の詳細を示すと，4時間で2 log IU/mL低下した症例は，TTでcoreは70 mutant，91 wildであり，同様に8時間の3例はTTかつdouble wildが1例，TGかつdouble mutantが2例であった．12時間かかった症例はTGかつdouble mutantであった．また，15日までに2例が陰性化，2

1）虎の門病院肝臓内科
2）虎の門病院肝臓研究室
*Corresponding author: suzunari@interlink.or.jp
＄利益相反申告：熊田博光≒Bristol-Myers Squibb
＜受付日2010年11月18日＞＜採択日2010年12月8日＞



Fig. 2 Changes in ALT over duration of study treatment

例が測定感度以下に低下している．次にFig. 2に示すようにALT値は7日で全例正常化し，途中中止の1例を除きその後も正常域を維持している．

投与中止例となった症例は60歳の女性で，開始7日目にはAST/ALTとも正常化し，10日目までは副反応もなく，ウイルス量も5.2から1.7と良好な減少を示した．開始10日目に高脂肪食を摂取後より軟便，下痢をきたし発熱と共に炎症所見の上昇が認められた．これに対して抗生剤の投与を開始ししだいに解熱傾向となった．肝胆道系酵素の上昇は当初認められず，ビリルビン値のみが上昇，16日目に6.5 mg/dlまで上昇したため服用を中止した．20日目よりAST優位の肝酵素の上昇が認められ投与30日目に432/315 IU/lとピークを迎えその後低下した．この間，胆道系酵素の上昇は一度も認められておらず，ビリルビン値も薬剤中止後速やかに低下している．ウイルスは15日目に1.2 log IU/mL＞陽性であったが，中止2週後に陰性化し，その後投与終了24週まで陰性を持続している．本症例のウイルス消失については，肝炎の再燃に伴いウイルス排除が起こった可能性も否定できないが肝酵素上昇のピークよりも前にすでにウイルスは消失しており，本治療薬による効果の可能性が高いと判断している．

考察：新たなC型慢性肝炎治療薬であるNS5A阻害剤とNS3阻害剤の併用投与における早期の抗ウイルス効果につき報告した．NS5Aは多機能性蛋白質であり，in vitroおよびin vivoにおけるHCVの複製に必要であり，ヒトでの相同体が知られていないことからHCV治療の標的として期待されている．また，非構造蛋白質(NS)3のN末端はセリンプロテアーゼ(NS3プロテアーゼ)であり，NS4Aと協力して蛋白質分解活性を有する複合体を形成する．NS3/4Aプロテアーゼ複合体の活性は，in vitroでのウイルス複製に非常に重要な役割を果たしており，今回の薬剤はNS3プロテアーゼに特異的な阻害活性を有している．

少数例の検討ではあるものの早期の抗ウイルス効果はこれまでに類を見ないくらい良好であり，15日目には40％の症例に陰性化が得られたということは対象がPEG＋Ribaのnull responderということを勘案すれば十分すぎる効果といえる．特にIL-28BがTGであり，coreがdouble mutantで，前回のPEG＋Riba治療がnull responderというような最難治例において，現状の治療ではSVRの望みがほとんどないような症例が3例とも投与開始後12時間以内にウイルスの十分な低下が得られていることは特筆すべきものがある．これまで1b型高ウイルス量症例に対する標準的治療では，約50％のSVRがえられるものの，その治療効果の向上のためには投与期間の延長や他の薬剤の併用などといった更なる負担が課せられてきた．今回の経口剤投与のみの治療においては，IFNに伴うような感冒様症状，食欲不振，貧血などの副反応は認められていない．我々はこれまでにテラプレビル単剤投与にてSVRを獲得した症例の報告をしてきた[2]．本症例は1b型で低ウイルス量であるものの副反応の出現もなく24週間の経口剤のみの投与で完全著効がえられた．また，最近ではpolymerase inhibitor（RG7128）とdanoprevirの組み合わせで早期に抗ウイルス効果が認められるという報告や[3]，danoprevir単独投与は早期に抗ウイルス効果を発揮すると共にHOMA-IRを改善するといった報告[4]もあり，IFNを使用しない治療法が盛んに試されまた治療効果に期待がもたれている．今回の症例が今後どのような経過をとるのかは投与予定期間の24週が終了してみなければ断定できないが，現時点ではこれまでの中で最も抗ウイルス効果の高い治療に無反応であった症例全てにおいてウイルスが陰性化したということは評価できることと考える．今後さらに経過を観察すると共に，副反応の出現にも注意を怠らないことが肝要であると思われる．

索引用語：C型肝炎ウイルス，NS5A阻害剤，プロテアーゼ阻害剤

文献：1）Akuta N, Suzuki F, Hirakawa M, et al. Hepatology 2010; 52 (2): 421—429　2）Suzuki F,

Suzuki Y, Akuta N, et al. J Clin Virol 2010; 47 (1): 76—78 3) Gane EJ, Roberts SK, Stedman CA, et al. Lancet 2010; 376 (9751): 1467—1475 4) Moucari R, Forestier N, Larrey D, et al. Gut 2010; 59 (12): 1694—1698

英文要旨

Effect of early antiviral agent therapy (NS3 and NS5A inhibitors) in chronic hepatitis C null responders

Yoshiyuki Suzuki[1]*, Hitomi Sezaki[1], Norio Akuta[1], Fumitaka Suzuki[1], Hiroya Seko[1], Norihiro Imai[1], Miharu Hirakawa[1], Yuusuke Kawamura[1], Tetsuya Hosaka[1], Masahiro Kobayashi[1], Satoshi Saitoh[1], Yasuji Arase[1], Kenji Ikeda[1], Mariko Kobayashi[2], Hiromitsu Kumada[1]

To further improve therapeutic effect on chronic hepatitis C, we have administered NS3 inhibitor and NS5A inhibitor together, and examined effects of early antiviral agent therapy. The subjects were five cases where interferon is ineffective (null responders). The NS5A and NS3 inhibitors are oral drugs and were daily administered for 24 weeks. Figure 1 shows time-dependent change of the number of viruses after the therapy started, and rapid decrease of viruses is recognized. Within 12 hours, HCV-RNA decreased by more than 2 log IU/ml in every patient. Two patients became negative for the virus by the 15th day after the therapy started. Furthermore, 80% of cases by the 28th day and all the cases by the 56th day became negative. The new therapy has manifested excellent early antiviral effect.

Key words: hepatitis C virus, NS5A inhibitor, protease inhibitor

Kanzo 2011; 52: 147—149

1) Department of Hepatology, Toranomon Hospital
2) Liver Research Laboratory, Toranomon Hospital
*Corresponding author: suzunari@interlink.or.jp

肝臓　52巻4号　255-257（2011）

＜速　報＞

B型慢性肝疾患に対する核酸アナログ療法によるHBs抗原消失とその関連因子の検討

保坂　哲也[1)*]　鈴木　文孝[1)]　小林　正宏[1)]　瀬古　裕也[1)]　今井　則博[1)]
平川　美晴[1)]　川村　祐介[1)]　瀬崎ひとみ[1)]　芥田　憲夫[1)]　鈴木　義之[1)]
斎藤　聡[1)]　荒瀬　康司[1)]　池田　健次[1)]　小林万利子[2)]　熊田　博光[1)]

緒言：B型肝疾患に対する核酸アナログ療法の有効性は広く知られており，経過観察期間が長くなるにつれ，B型肝炎治療の最終目標であるHBs抗原（HBsAg）消失を得られる症例も散見されている．本邦及び海外からいくつかの報告もあるが[1)~4)]，いまだ長期に渡る核酸アナログ使用例での報告はない．今回我々は長期間の核酸アナログ治療によるHBsAg消失とその関連因子について検討した．

対象と方法：1995年～2006年までに当院でB型慢性肝疾患に対して，ラミブジン単独投与を開始した769例を対象とした．これら全ての症例で6カ月以上のHBV持続感染を確認した．核酸アナログ投与内容の内訳はラミブジン単独投与継続306例，ラミブジン投与開始後耐性ウイルス出現に対してラミブジン＋アデフォビル併用を行った症例297例，ラミブジン→エンテカビルへの切り替え症例166例であった．これらの症例のうち，何らかの理由で投与中止した症例は46例存在し，それ以外の症例はすべて継続投与を行った．HBsAg測定はCLIA法（ARCHITECT® HBsAg QT）を用いた．

Table　Factors associated with HBsAg clearance by univariate and multivariate analysis.

	Univariate		Multivariate	
factors	Hazard Ratio (95%CI)	P	Hazard Ratio (95%CI)	P
Age (≥50yr)	0.94 (0.48-1.89)	0.865		
Gender (F)	0.59 (0.21-1.68)	0.323		
Family history of HBV infection	**0.43 (0.22-0.84)**	**0.014**		
Presence of cirrhosis	0.79 (0.56-1.12)	0.192		
Previous IFN therapy	**2.70 (1.31-5.59)**	**0.007**	**2.96 (1.34-6.54)**	**0.008**
HBV genotype (A)	**3.39 (2.27-5.08)**	**<0.0001**	**3.64 (2.40-5.52)**	**<0.0001**
HBeAg (positive)	1.23 (0.61-2.48)	0.563		
HBV DNA (≥6.0 logcopies/mL)	1.20 (0.52-2.78)	0.674		
HBsAg (<2000 IU/mL)	1.40 (0.70-2.80)	0.346		
ALT (≥300 IU/L)	**1.47 (1.02-2.11)**	**0.040**		
Platelets count (<1.2×10^5/mm^3)	0.91 (0.34-2.43)	0.123		
Treatment response at 6 months				
HBeAg positive → clearance	**3.15 (1.49-6.66)**	**0.003**	**2.22 (1.01-4.88)**	**0.046**
HBV DNA (<2.6 logcopies/mL)	**3.56 (1.22-10.4)**	**0.021**	**4.07 (1.36-12.2)**	**0.012**

The bolded numbers: statically significant.
Abbreviation: HBsAg, Hepatitis B surface antigen; IFN, interferon; HBeAg: Hepatitis B envelope antigen

1）虎の門病院肝臓センター
2）虎の門病院肝臓研究室
*Corresponding author: hosa-p@toranomon.gr.jp
＜受付日2011年2月1日＞＜採択日2011年3月2日＞

ラミブジン開始後のHBsAg消失に寄与する因子についてCox比例ハザードモデルを用いて，単変量及び多変量解析を行い検討した．

結果：ラミブジン投与開始からの観察期間の中央値は6.3年（0.7–13.5年）であった．ラミブジン投与前にIFN治療歴を有する症例が297例（39%）存在した（投与期間の中央値は27週（2–575週））．HBV感染の家族歴を有する症例が538例（70%）存在した．ラミブジン投与開始後のHBsAg消失は33例で認められた（内訳は投与中消失31例，投与終了後消失2例）．全体での累積HBsAg消失率は5年：1.8%，10年：7.3%であった．HBsAg消失に寄与する因子について単変量解析を行ったところ，抽出された因子は，家族歴あり（48% vs. 74%），IFN治療歴あり（64% vs. 37%），genotype A（25% vs. 2.6%），開始時ALT高値（300 IU/L以上）（33% vs. 20%），治療開始6カ月以内のHBe抗原消失（30% vs. 12%：HBeAg持続陽性例や持続陰性例に比して），治療開始後6カ月時点でのHBVDNA陰性化（<2.6 log copies/ml）（85% vs. 67%）の6因子が抽出された（Table）．また治療法別で検討すると，ラミブジン単独またはエンテカビル切り替え症例では，ラミブジン＋アデフォビル併用療法症例に比してHBsAg消失率が高率であった（P＝0.014）．

上記の因子を用いて，HBsAg消失に寄与する因子について多変量解析を行ったところ，独立因子としてgenotype A，IFN治療歴，治療開始6カ月時点でHBeAg陽性→陰性化，治療開始後6カ月時点でのHBVDNA陰性化の4因子が抽出された（Table）．

考察：今回の検討では核酸アナログ投与後のHBsAg消失にはHBV genotypeが強く関わっている事が分かった．これまでテルビブジンやPegIFNでの報告のように[4][5]，genotype AではHBsAg量の低下が，他のgenotypeより起こりやすいため，HBsAg消失が起こりやすいと考えられる．またIFN治療歴や核酸アナログ治療早期の反応性などがHBsAg消失に寄与し，治療開始時ALTの上昇が強い症例でもHBsAgが消失しやすい傾向にあったことから，核酸アナログ治療によりHBsAgを消失させるためには，核酸アナログ自体の抗ウイルス作用だけでなく，宿主の免疫反応が必要と推察される．今後HBsAg消失を目指した，核酸アナログ治療法の工夫が望まれる．この研究はラミブジン投与症例での検討であるが，今後は現在の標準治療であり，薬剤耐性出現が極めて低率のエンテカビル投与症例での検討も必要と思われる．

索引用語：HBsAg，核酸アナログ，IFN

文献：1）Kobayashi M, Suzuki F, Akuta N, et al. J Med Virol 2007; 79: 1472—1477　2）Manesis EK, Hadziyannis ES, Angelopoulou OP, et al. Antiviral Ther 2007; 12: 73—82　3）Gish RG, Chang TT, Lai CL, et al. J Viral Hepat 2010; 17: 16—22　4）Wursthorn K, Jung M, Riva A, et al. Hepatology 2010；52：1612—1620　5）Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Antivir Ther 2009; 14: 1183—1188

英文要旨

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analogues treatment in chronic hepatitis B

Tetsuya Hosaka[1]*, Fumitaka Suzuki[1], Masahiro Kobayashi[1], Yuya Seko[1], Norihiro Imai[1], Miharu Hirakawa[1], Yusuke Kawamura[1], Hitomi Sezaki[1], Norio Akuta[1], Yoshiyuki Suzuki[1], Satoshi Saitoh[1], Yasuji Arase[1], Kenji Ikeda[1], Mariko Kobayashi[2], Hiromitsu Kumada[1]

Clearance of HBsAg is considered the ultimate goal in the treatment for chronic hepatitis B. We analyzed clinical factors associated with HBsAg clearance during long-term nucleot(s)ide analogue treatment. By univariate analysis, HBV genotype, family history of HBV infection, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were significant predictive factors. By multivariate analysis, HBV genotype, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were independent and significant predictive factors of HBsAg clearance. We conclude that patients with genotype A have high probability of HBsAg clearance, and it seems that not only the antiviral potential of nucleot(s)ide analogue but host immune response is needed to achieve HBsAg clearance.

Key words: hepatitis B surface antigen, nucleot(s)ide analogues, interferon

Kanzo 2011; 52: 255—257

1) Department of Hepatology, Toranomon Hospital, Tokyo
2) Department of Research Institute for Hepatology, Toranomon Branch Hospital, Kawasaki
*Corresponding author: hosa-p@toranomon.gr.jp

肝臓　52巻11号　756-757（2011）

＜短　報＞

コバス TaqMan HBV「オート」v2.0における同一時の血清検体と血漿検体のHBV DNA検出率の検討

小林万利子[1)*]　鈴木　文孝[2)]　鈴木　義之[2)]　芥田　憲夫[2)]　瀬崎ひとみ[2)]
川村　祐介[2)]　瀬古　裕也[2)]　保坂　哲也[2)]　小林　正宏[2)]　斉藤　聡[2)]
荒瀬　康司[2)]　池田　健次[2)]　熊田　博光[2)]

緒言：HBV DNAの測定は，1996年に分岐HBV DNAプローブ法が臨床応用されてから，検査技術の進歩に伴いTMA（transcription-mediated amplification）法やPCR法などの高感度な測定法の開発が進んできた．現在，日常の臨床で使用されているreal-time PCR法は，HBV DNA量が1.5～2.0 Log copies/mL程度まで検出可能となった．今回我々は，TaqMan HBV v2.0法（コバスTaqMan HBV「オート」v2.0[1)]；ロシュ・ダイアグノスティックス，東京）を用い，血清と血漿の同時採血を行い，各検体の有用性について検討を行ったので報告する．

対象と方法：対象は，B型慢性肝炎および肝硬変の成人でEntecavir投与1年以上経過しALT（alanine aminotransferase）値が30 IU/l以下を持続している52症例（104検体）とした．内訳は，男性29例（55.8%），年齢52歳：中央値（27～81歳）であった．HBV genotypeはgenotype A：2例，genotype B：5例，genotype C：44例，typing不能：1例であった．52症例に対し治療効果の均一化を計るため同一検体で2回の採血を実施しHBV DNAを測定した．2回目のポイントの採血は，1回目の採血後，8週±2週の間に実施した．血清用採血管で全血5 mLと血漿用採血管（EDTA-2K）で全血8 mLを採血，速やかに遠心分離後，TaqMan HBV v2.0法（最小検出感度は，血清検体：2.0 Log copies/mL，血漿検体：1.7 Log copies/mL）にて測定を行った．統計解析は，統計解析ソフトウェアSTAT Flex ver. 5.0を用い，$P<0.05$で有意とした．本試験は，当院の倫理審査委員会の承認を受け，実施についてのインフォームド・コンセントを行った．

結果：血清・血漿ペア検体104例のうち，血清と血漿の両者でHBV DNAを検出したのは，25例（24.0%），両者ともに検出不能は，41例（39.4%）であったが，血清で検出したが血漿では検出不能であったのは，6例（5.8%）であり，血漿で検出したが血清では検出不能であったのは，32例（30.8%）で，血漿での検出率は，血清より有意（$P<0.001$［McNemar検定］）に高率であった（Table 1）．

考察：核酸アナログ製剤を長期に投与することによりその耐性株の出現および肝炎の悪化が認められることから，特に若年者においては核酸アナログ製剤を中止することも考え，HBV DNA量をはじめ，HBs抗原，HBコア関連抗原などの種々のHBVマーカーについて検討が行われている[2)]．Drug freeが可能な症例選定の必要条件の一つはHBV DNAの持続陰性化であり[3)]，投与中止後ALT値の再上昇による重症化・劇症化が懸念されることより，高感度にHBV DNAを検出することが重要である可能性がある．

そこで今回，我々は臨床検体を用いTaqMan HBV

Table 1　Detail correlation between plasma specimen (EDTA-2K) and serum specimen

		Serum	
		detected	not detected
plasma (EDTA-2K)	detected	25 (24.0%)	32* (30.8%)
	not detected	6* (5.8%)	41 (39.4%)

*: $P<0.001$［McNemar検定］

1）虎の門病院肝臓研究室
2）虎の門病院肝臓センター
*Corresponding author: vj7m-kbys@asahi-net.or.jp
＜受付日2011年8月19日＞＜採択日2011年9月2日＞

v2.0 の血清検体と血漿検体の有用性の検討を行った．対象の 104 検体のうち血清または血漿のいずれかで HBV DNA を検出したのは，血清は 5.8％に対し血漿では 30.8％と血漿での HBV DNA の検出率は統計学的有意差（P＜0.001）をもって高率であった．一方，血清で HBV DNA を検出したが血漿では検出不能であった検体も 5.7％存在したが，年齢，性別，genotype などに一定の偏りは無く，この現象は，最小検出感度未満の極めて低濃度の検体で発生するバラツキに起因する確率論的な現象と考えられた．

以上から，血漿検体を用いることにより血清検体より高感度に HBV DNA を測定することが可能となった．今後より高感度な測定が必要な分野での臨床応用が期待される．

索引用語：B 型肝炎ウイルス，
TaqMan PCR 法，高感度

文献：1）Goedel S, Rullkoetter M, Weisshaar S, et al. Journal of Clinical Virology 2009; 45: 232—236　2）Matsumoto A, Tanaka E, Minami N, et al. Hepatology Research 2007; 37: 661—666　3）田中榮司．厚生科学研究費補助金（肝炎等克服緊急対策研究事業）総括研究報告書，2010，H21-肝炎—一般-001

英文要旨

The evaluation of the sensitivity between serum and plasma specimen for COBAS TaqMan HBV v2.0

Mariko Kobayashi[1)*], Fumitaka Suzuki[2)], Yoshiyuki Suzuki[2)], Norio Akuta[2)], Hitomi Sezaki[2)], Yusuke Kawamura[2)], Yuya Seko[2)], Tetsuya Hosaka[2)], Masahiro Kobayashi[2)], Satoshi Saitoh[2)], Yasuji Arase[2)], Kenji Ikeda[2)], Hiromitsu Kumada[2)]

The sensitivity in serum and plasma for HBV DNA was evaluated by using 104 clinical specimens from 52 patients who were treated with entecavir for ≥1 year and continued ALT levels ≤30 IU/l. The measurement employed the COBAS TaqMan HBV v2.0. Twenty-five specimens (24.0%) were detected from both serum and plasma, and 41 specimens (39.4%) were not detected from both. On the other hand, there were 32 specimens (30.8%) with detectable from plasma but undetectable from serum, and only 6 specimens (5.8%) with detectable from serum but undetectable from plasma. This result suggested the sensitivity of HBV DNA using plasma specimen is more sensitive than that of serum specimen with statistical significance (p＜0.001).

Key words: hepatitis B virus, TaqMan, high sensitivity

Kanzo 2011; 52: 756—757

1）Research Institute for Hepatology, Toranomon Hospital
2）Department of Hepatology, Toranomon Hospital
*Corresponding author: vj7m-kbys@asahi-net.or.jp